Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Comment by DeathXray33on Sep 17, 2024 3:24pm
173 Views
Post# 36227722

RE:Last NR is two weeks old.

RE:Last NR is two weeks old.
Lesalpes29 wrote: Really need an other good one. A possible deal on the viruses side? GL


"The global herpes simplex virus treatment market size was estimated at USD 2.47 billion in 2023 and is expected to grow at a compound annual growth rate (CAGR) of 8.1% from 2024 to 2030." ---------------------------- "The prevalence of herpes simplex virus (HSV) infection is on the rise. According to an estimate from WHO, as of April 2023 approximately 3.7 billion people under age 50, which account for 67% of the population, are living with HSV-1 infection and an estimated 491 million people between ages 15 and 49 years are living with HSV-2 infection. Such a high number of HSV cases will require adequate therapeutic management." ------------------------------------ The increase in government funding for promoting research in HSV infection space is anticipated to drive the market growth during the forecast period. HSV is a kind of STD with limited treatment approaches; hence, governments, public & private organizations, and nonprofit organizations are granting funds to boost research activities to develop novel therapeutic approaches in HSV and other sexually transmitted diseases." ------------------------------------------- https://www.grandviewresearch.com/industry-analysis/herpes-simplex-virus-treatment-market-report
<< Previous
Bullboard Posts
Next >>